Vergoeding 2020-2024 voor ATC-subgroep A10AE : Langwerkende insulines voor injectie
- Raming voor de totale Zvw-populatie
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| A10AE04 Insuline glargine (Lantus ®) | 39.615.900 | 34.040.400 | 34.788.500 | 34.210.000 | 32.244.100 |
| A10AE05 Insuline detemir (Levemir ®) | 8.990.100 | 7.405.700 | 7.083.700 | 6.288.800 | 5.591.300 |
| A10AE06 Insuline degludec (Tresiba ®) | 19.560.200 | 19.769.600 | 21.697.200 | 21.854.200 | 21.795.100 |
| A10AE54 Insuline glargine met lixisenatide (Suliqua ®) | 452.150 | 346.850 | 262.030 | 216.630 | 195.200 |
| A10AE56 Insuline degludec met liraglutide (Xultophy ®) | 2.864.800 | 2.210.500 | 1.913.900 | 1.725.500 | 1.535.400 |
| Totaal | 71.483.150 | 63.773.050 | 65.745.330 | 64.295.130 | 61.361.100 |